课题基金 / 基金详情

FAME 1 - Eye

FAME 1 - Eye
名望 1 - 眼睛
批准号:
nhmrc : GNT1069147
负责人:
Prof Alicia Jenkins
金额:
$275.46万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2014
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2014-01-01 至 --
关键词:

项目摘要

项目成果

Prof Alicia Jenkins的其他基金

相似基金

相关文献

中文摘要
翻译
糖尿病是导致成年人失明的最常见原因之一。视力丧失是不可逆转的,是糖尿病最可怕的并发症。一种名为非诺贝特的降血脂药物在澳大利亚有售,已被证明可将2型糖尿病患者的眼睛损伤减少35-40%,并在1型糖尿病动物模型中预防眼睛损伤。本研究将评估非诺贝特对450例早期糖尿病眼损伤的成人1型糖尿病患者的潜在益处。
英文摘要
Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Better Outcomes through Innovations in Clinical Trials: from Personalised Medicine to Population Health
  • 批准号:
    nhmrc : 1150467
  • 项目类别:
    Program Grants
  • 资助金额:
    $814.53万
  • 财政年份:
    2019
  • 负责人:
    Prof Alicia Jenkins
  • 依托单位:
Better Outcomes through Innovations in Clinical Trials: from Personalised Medicine to Population Health
  • 批准号:
    nhmrc : GNT1150467
  • 项目类别:
    Programs
  • 资助金额:
    $1221.55万
  • 财政年份:
    2019
  • 负责人:
    Prof Alicia Jenkins
  • 依托单位:
Biomarkers, Related Mechanisms and Technology to Improve Diabetes Outcomes
  • 批准号:
    nhmrc : 1121272
  • 项目类别:
    Practitioner Fellowships
  • 资助金额:
    $32.44万
  • 财政年份:
    2017
  • 负责人:
    Prof Alicia Jenkins
  • 依托单位:
Biomarkers, Related Mechanisms and Technology to Improve Diabetes Outcomes
  • 批准号:
    nhmrc : GNT1121272
  • 项目类别:
    Practitioner Fellowships
  • 资助金额:
    $47.45万
  • 财政年份:
    2017
  • 负责人:
    Prof Alicia Jenkins
  • 依托单位:
海外基金